<DOC>
	<DOCNO>NCT00002324</DOCNO>
	<brief_summary>PRIMARY : To compare effect nevirapine versus placebo alone combination zidovudine ( AZT ) CD4 T-cell count percentage 3 6 month treatment . To evaluate safety tolerance nevirapine alone combination AZT . SECONDARY : To compare effect various treatment combination virologic immunologic marker .</brief_summary>
	<brief_title>The Safety Effectiveness Nevirapine Zidovudine , Given Separately Together , HIV-1 Infected Patients Who Have No Symptoms Disease</brief_title>
	<detailed_description>In Part I , patient prior AZT therapy receive either nevirapine placebo combination AZT . In Part II , patient nucleoside naive receive either nevirapine matching placebo . After 6 month , patient receive open-label nevirapine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis ( trimethoprimsulfamethoxazole , dapsone , aerosolized pentamidine ) , discretion investigator . Antifungal prophylaxis oral fluconazole ketoconazole . Antiviral prophylaxis herpes simplex virus &lt; = 1000 mg/day oral acyclovir . Dilantin prevention treatment seizure . Patients must : Asymptomatic HIV1 infection , positive serum antibody HIV1 determine ELISA Western blot . CD4 count 200500 cells/mm3 within 428 day prior study entry . No condition indicative AIDS . None constitutional symptom specifically exclude . Prior AZT 324 month ( amend 04/04/94 ) immediately prior study entry ( Part I ) OR prior AZT ( Part II ) . Consent parent guardian le 18 year age . NOTE : Coenrollment protocol involve another investigational drug biologic permit . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy limit cutaneous basal cell carcinoma . Psychiatric condition sufficient impair compliance protocol requirement . Concurrent Medication : Excluded : Investigational drug study drug . Systemic glucocorticoid steroid hormone . Dicumarol , warfarin , anticoagulant medication . Cimetidine . Tolbutamide . Doxycycline . Chloramphenicol . Phenobarbital barbiturates . Foscarnet . Erythromycin . Amoxicillinclavulanate ( Augmentin ) . Ticarcillin clavulanate ( Timentin ) . Biologic response modifier ( alpha interferon , IL2 , immune modulators ) . Patients follow condition exclude : History clinically important disease ( i.e. , one preclude participation study ) . Prior Medication : Excluded : Antiretroviral medication AZT . Excluded within 4 week prior study entry : Immunosuppressive cytotoxic drug experimental drug . Systemic glucocorticoid steroid hormone . Dicumarol , warfarin , anticoagulant medication . Cimetidine . Tolbutamide . Doxycycline . Chloramphenicol . Phenobarbital barbiturates . Foscarnet . Erythromycin . Amoxicillinclavulanate ( Augmentin ) . Ticarcillin clavulanate ( Timentin ) . Biologic response modifier ( alpha interferon , IL2 , immune modulators ) . Required ( patient Part I ) : Prior AZT 500600 mg daily least 3 month 24 month immediately prior study entry . Chronic use alcohol drug sufficient impair compliance protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>